Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by Disorder Type
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Gastric Motility Disorders
4.1.2. Restraints
4.1.2.1. Limited Drugs for Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs
6. By Drug Type
6.1. Introduction
6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Type
6.1.2. Market Attractiveness Index, By Drug Type
6.2. Prokinetic Agents*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Parasympathomimetics
6.4. Opioid Antagonists
6.5. Antidiarrheals
6.6. Anti-Emetic Drugs
6.7. Antibiotics
6.8. Others
7. By Disorder Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
7.1.2. Market Attractiveness Index, By Disorder Type
7.2. Achalasia*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Esophageal spasms
7.4. Heartburn or Gastroesophageal Reflux Disease (GERD)
7.5. Gastroparesis
7.6. Irritable Bowel Syndrome (IBS)
7.7. Fecal incontinence
7.8. Intestinal Pseudo-obstruction
7.9. Others
8. By Distribution Channel
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
Key Market Players
11.1. Pfizer Inc.*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue’s
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals etc.
11.1.5. SWOT Analysis
11.2. Eisai Co., Ltd.
11.3. Mallinckrodt
11.4. Salvus Pharma
11.5. Atmo Biosciences
11.6. AdvaCare Pharma
11.7. Avenacy
11.8. VAIKUNTH CHEMICALS PVT. LTD.
11.9. Healthy Inc
11.10. Bhumi Pharmaceuticals
* Similar data will be provided for each market player.
Emerging Market Players
11.11. Processa Pharmaceuticals, Inc.*
11.11.1. Pipeline Products Description
11.11.2. Product Key Performance Indicators (KPIs)
11.11.3. Key Activities
11.11.4. Market Entry Timelines
11.11.5. Product Penetration Rate
11.11.6. Sales Estimation and Projections
11.12. Vanda Pharmaceuticals Inc.
11.13. Renexxion Ireland Limited
11.14. Aclipse Therapeutics
* Similar data will be provided for each market player.
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us